Understanding Suspension 100 Dragon Pharma
Testosterone aqueous suspension is a fast-acting androgenic steroid research compound formulated as an immediate-release suspension for in-vitro laboratory investigations. This pharmaceutical preparation from Dragon Pharma provides researchers with a water-based testosterone formulation for studying androgenic receptor interactions and steroid pharmacokinetics. The aqueous suspension format offers unique research advantages for examining rapid-onset androgenic effects in controlled laboratory environments. Our Stroid UK Shop maintains strict quality control standards for all testosterone-based research compounds.
Laboratory Applications
Researchers investigate this compound for studying androgenic receptor binding affinity, tissue-selective androgen activity, and steroid metabolic pathways in cellular models. The suspension formulation enables examination of immediate bioavailability characteristics and pharmacokinetic profiles in research settings. Laboratory studies explore testosterone’s effects on protein synthesis pathways, nitrogen retention mechanisms, and cellular growth factor modulation. Scientists utilise this compound when examining testosterone aqueous suspension preparations alongside other androgenic steroids for comparative research protocols.
Specifications
| Parameter | Specification |
|---|---|
| Concentration | 100mg/ml |
| Volume | 10ml vial |
| Formulation | Aqueous suspension |
| Manufacturer | Dragon Pharma |
| Storage | Room temperature, protect from light |
| Molecular Formula | C₁₉H₂₈O₂ |
| CAS Number | 58-22-0 |
| Molecular Weight | 288.42 g/mol |
This research compound complements studies involving selective androgen receptor modulators and peptide research compounds for comprehensive androgenic pathway investigations.
Research Compliance
This testosterone aqueous suspension is supplied exclusively for in-vitro research purposes and laboratory investigations. Not approved for human consumption, clinical use, or therapeutic applications. Researchers must comply with relevant institutional guidelines and safety protocols when handling androgenic research compounds.
